HR 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act]

HR 6610 in plain English: This bill would regulate pharmacy benefit managers (PBMs) operating within Federal Employee Health Benefit Plans by requiring them to meet certain payment standards when reimbursing pharmacies and imposing financial penalties for violations.

Stated purpose

The bill aims to limit the costs and practices of pharmacy benefit managers (PBMs) within Federal Employee Health Benefit Plans by setting rules on how PBMs reimburse pharmacies and pass drug rebates on to patients.

Key points

• Requires PBMs to pay pharmacies a professional dispensing fee equal to 4% of the drug cost or $50, whichever applies
• Imposes a civil monetary penalty of $10,000 per violation on pharmacy benefit managers that break the rules
• Caps total penalties on a PBM at $100,000 over any 10-year period for violations tied to a carrier's health benefit plans
• Caps total penalties on a carrier at $50,000 over any 10-year period
• Requires violators to submit a remediation plan after penalties are imposed

Arguments supporters make

• Federal employees and their families would see real savings at the pharmacy counter because rebates from drug makers would directly lower what they pay out of pocket, instead of being kept by the PBM.
• Independent pharmacies would be protected from being pushed out of networks or steered around by PBMs that own competing pharmacies, helping keep local pharmacies in business and giving patients more choice.
• Setting clear, standardized reimbursement rules prevents PBMs from using post-claim fees and adjustments to quietly reduce what pharmacies actually get paid, making the system more transparent and fair.

Arguments opponents make

• Fixing reimbursement rates and dispensing fees by law removes flexibility that PBMs and insurers use to negotiate lower overall drug costs, which could end up raising premiums for federal employees rather than saving them money.
• Restricting how PBMs build networks and direct patients to certain pharmacies could reduce the ability to steer patients toward lower-cost options, potentially increasing total drug spending in the federal health program.
• Rules designed for the federal employee market may not translate well to the wide variety of health plans and pharmacies involved, creating administrative complexity and compliance burdens without guaranteeing the intended savings reach patients.

Tradeoffs

Protecting pharmacies and reducing patient costs at the counter may limit the tools PBMs use to negotiate bulk discounts, creating tension between helping individual patients and keeping overall plan costs low; gains for independent pharmacies come at the cost of constraints on PBM network and business flexibility.

Current status in Congress: In committee.

NewsClear — neutral news & congressional tracking · Bill of the Week